« Back to Record
Citation APA

Loibl, S., Von Minckwitz, G., Schneeweiss, A., Paepke, S., Lehmann, A., Rezai, M., Zahm, D. D., Sinn, P., Khandan, F., Eidtmann, H., Dohnal, K., Heinrichs, C., Huober, J., Pfitzner, B. B., Fasching, P. A., Andre, F., Lindner, J. J., Sotiriou, C., Dykgers, A., Guo, S., Gade, S., Nekljudova, V., Loi, S., Untch, M., & Denkert, C. (2014). PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. Journal of clinical oncology, 32(29), 3212-3220. doi:10.1200/JCO.2014.55.7876


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/186695

Loibl, S., Von Minckwitz, G., Schneeweiss, A., Paepke, S., Lehmann, A., Rezai, M., Zahm, D. D., Sinn, P., Khandan, F., Eidtmann, H., Dohnal, K., Heinrichs, C., Huober, J., Pfitzner, B. B., Fasching, P. A., Andre, F., Lindner, J. J., Sotiriou, C., Dykgers, A., Guo, S., Gade, S., Nekljudova, V., Loi, S., Untch, M., & Denkert, C. (2014). PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. Journal of clinical oncology, 32(29), 3212-3220. doi:10.1200/JCO.2014.55.7876